Arch Biopartners
@archbiopartners.com
Arch Biopartners is a therapeutic biotech company focused on developing novel, on-target drugs for acute kidney injury (AKI) and chronic kidney disease (CKD).
🔎 A Pediatric Nephrology study (@ped-neph.bsky.social link.springer.com/article/10.1007/s00467-023-06197-1) shows machine learning can help predict AKI in children after heart surgery. Arch’s trials are evaluating drugs to prevent AKI in high-risk patients.
🔬 archbiopartners.com/our-science
#CSAKI
🔬 archbiopartners.com/our-science
#CSAKI
Predicting pediatric cardiac surgery-associated acute kidney injury using machine learning - Pediatric Nephrology
Background Prediction of cardiac surgery-associated acute kidney injury (CS-AKI) in pediatric patients is crucial to improve outcomes and guide clinical decision-making. This study aimed to develop a ...
link.springer.com
December 12, 2025 at 7:52 PM
🔎 A Pediatric Nephrology study (@ped-neph.bsky.social link.springer.com/article/10.1007/s00467-023-06197-1) shows machine learning can help predict AKI in children after heart surgery. Arch’s trials are evaluating drugs to prevent AKI in high-risk patients.
🔬 archbiopartners.com/our-science
#CSAKI
🔬 archbiopartners.com/our-science
#CSAKI
📚 JACC: Heart Failure (www.jacc.org/doi/10.1016/j.jchf.2024.11.007): CKD in U.S. veterans with heart failure raised hospitalization and death risk across all ejection fractions. Underscores need for targeted CKD therapies.
🔬 archbiopartners.com/our-science/ckd-platform
#CKD #KidneyCare #NephSky
🔬 archbiopartners.com/our-science/ckd-platform
#CKD #KidneyCare #NephSky
Outcomes of KDIGO-Defined CKD in U.S. Veterans With HFpEF, HFmrEF, and HFrEF:
www.jacc.org
December 10, 2025 at 3:52 PM
📚 JACC: Heart Failure (www.jacc.org/doi/10.1016/j.jchf.2024.11.007): CKD in U.S. veterans with heart failure raised hospitalization and death risk across all ejection fractions. Underscores need for targeted CKD therapies.
🔬 archbiopartners.com/our-science/ckd-platform
#CKD #KidneyCare #NephSky
🔬 archbiopartners.com/our-science/ckd-platform
#CKD #KidneyCare #NephSky
📈 As CKD cases continue to rise in Canada, The Kidney Foundation is calling for a National CKD Framework at kidney.ca/Get-Involved/Advocacy/National-CKD-Framework
Arch is advancing CKD therapeutics developed in Calgary.
🔬 archbiopartners.com/our-science/ckd-platform
#CKD #KidneyCare #NephSky
Arch is advancing CKD therapeutics developed in Calgary.
🔬 archbiopartners.com/our-science/ckd-platform
#CKD #KidneyCare #NephSky
National CKD Framework
This Framework will be Canada’s first comprehensive, evidence-based roadmap designed to transform kidney health outcomes across the country - and one that governments can use to inform policy, plannin...
kidney.ca
December 5, 2025 at 2:55 PM
📈 As CKD cases continue to rise in Canada, The Kidney Foundation is calling for a National CKD Framework at kidney.ca/Get-Involved/Advocacy/National-CKD-Framework
Arch is advancing CKD therapeutics developed in Calgary.
🔬 archbiopartners.com/our-science/ckd-platform
#CKD #KidneyCare #NephSky
Arch is advancing CKD therapeutics developed in Calgary.
🔬 archbiopartners.com/our-science/ckd-platform
#CKD #KidneyCare #NephSky
📈 GBD study @thelancet.com, CKD in top 10 causes of death. @ctvnewscalgary.bsky.social reports cases have doubled in Canada www.ctvnews.ca/video/2025/12/01/ctv-national-news-more-canadians-living-with-chronic-kidney-disease/
🔬 archbiopartners.com/our-science/ckd-platform
#CKD #KidneyCare #NephSky
🔬 archbiopartners.com/our-science/ckd-platform
#CKD #KidneyCare #NephSky
CTV National News: More Canadians living with chronic kidney disease
New data reveals chronic kidney disease is claiming the lives of more Canadians than ever before. Kathy Le on the health crisis.
www.ctvnews.ca
December 3, 2025 at 6:17 PM
📈 GBD study @thelancet.com, CKD in top 10 causes of death. @ctvnewscalgary.bsky.social reports cases have doubled in Canada www.ctvnews.ca/video/2025/12/01/ctv-national-news-more-canadians-living-with-chronic-kidney-disease/
🔬 archbiopartners.com/our-science/ckd-platform
#CKD #KidneyCare #NephSky
🔬 archbiopartners.com/our-science/ckd-platform
#CKD #KidneyCare #NephSky
🧬 2023 Antioxidants review www.mdpi.com/2076-3921/12... links oxidative stress to AKI, CKD, and cardiovascular risk.
Arch is advancing Phase II trials targeting inflammation and injury before kidney damage is irreversible.
🔬 archbiopartners.com/our-science/lsaltpeptide
#AKI #KidneyCare #NephSky
Arch is advancing Phase II trials targeting inflammation and injury before kidney damage is irreversible.
🔬 archbiopartners.com/our-science/lsaltpeptide
#AKI #KidneyCare #NephSky
www.mdpi.com
December 3, 2025 at 4:51 AM
🧬 2023 Antioxidants review www.mdpi.com/2076-3921/12... links oxidative stress to AKI, CKD, and cardiovascular risk.
Arch is advancing Phase II trials targeting inflammation and injury before kidney damage is irreversible.
🔬 archbiopartners.com/our-science/lsaltpeptide
#AKI #KidneyCare #NephSky
Arch is advancing Phase II trials targeting inflammation and injury before kidney damage is irreversible.
🔬 archbiopartners.com/our-science/lsaltpeptide
#AKI #KidneyCare #NephSky
📚 Nov 2025 study in JCVA jcvaonline.com/article/S1053-0770(25)00632-9/fulltext In >1,000 cardiac surgery patients, elevated hemolysis index, and longer bypass time predicted AKI. Supports inflammation-targeted CS-AKI therapies.
🔬 archbiopartners.com/our-science/lsaltpeptide/
#CSAKI #LSALTpeptide
🔬 archbiopartners.com/our-science/lsaltpeptide/
#CSAKI #LSALTpeptide
Hemolysis Index and Cardiopulmonary Bypass Time as Predictors of Cardiac Surgery-associated Acute Kidney Injury: An Observational Cohort Study
Acute kidney injury (AKI) is a common and serious complication of cardiac surgery,
often linked to the use and duration of cardiopulmonary bypass (CPB). The Hemolysis
Index (HI) has been proposed as a...
jcvaonline.com
November 29, 2025 at 3:20 AM
📚 Nov 2025 study in JCVA jcvaonline.com/article/S1053-0770(25)00632-9/fulltext In >1,000 cardiac surgery patients, elevated hemolysis index, and longer bypass time predicted AKI. Supports inflammation-targeted CS-AKI therapies.
🔬 archbiopartners.com/our-science/lsaltpeptide/
#CSAKI #LSALTpeptide
🔬 archbiopartners.com/our-science/lsaltpeptide/
#CSAKI #LSALTpeptide
📚 KDIGO 2022 guideline - @theisn.org - www.kidney-international.org/article/S008... Managing diabetic CKD is complex and current treatments rely on broad effects.
On-target approaches are needed.
🔬 archbiopartners.com/our-science/ckd-platform
#CKD #KidneyCare #NephSky
On-target approaches are needed.
🔬 archbiopartners.com/our-science/ckd-platform
#CKD #KidneyCare #NephSky
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
This article is published as part of a supplement supported by Kidney Disease: Improving
Global Outcomes (KDIGO). The development and publication of this guideline were supported
by KDIGO. The opinion...
www.kidney-international.org
November 25, 2025 at 4:18 PM
📚 KDIGO 2022 guideline - @theisn.org - www.kidney-international.org/article/S008... Managing diabetic CKD is complex and current treatments rely on broad effects.
On-target approaches are needed.
🔬 archbiopartners.com/our-science/ckd-platform
#CKD #KidneyCare #NephSky
On-target approaches are needed.
🔬 archbiopartners.com/our-science/ckd-platform
#CKD #KidneyCare #NephSky
📚 A 2022 Kidney International Supplement @theisn.org - www.kisupplements.org/article/S215... shows rising CKD rates and gaps in diagnosis and treatment. More precise, pathway-focused therapies are needed.
🔬 archbiopartners.com/our-science/ckd-platform/
#CKD #KidneyCare #NephSky
🔬 archbiopartners.com/our-science/ckd-platform/
#CKD #KidneyCare #NephSky
Epidemiology of chronic kidney disease: an update 2022
Chronic kidney disease is a progressive condition that affects >10% of the general
population worldwide, amounting to >800 million individuals. Chronic kidney disease
is more prevalent in older indivi...
www.kisupplements.org
November 19, 2025 at 7:22 PM
📚 A 2022 Kidney International Supplement @theisn.org - www.kisupplements.org/article/S215... shows rising CKD rates and gaps in diagnosis and treatment. More precise, pathway-focused therapies are needed.
🔬 archbiopartners.com/our-science/ckd-platform/
#CKD #KidneyCare #NephSky
🔬 archbiopartners.com/our-science/ckd-platform/
#CKD #KidneyCare #NephSky
📚 @thelancet.com study - www.thelancet.com/journals/lan... - confirms CKD has entered the top 10 causes of death worldwide.
Arch is advancing IL-32–targeting drug candidates to address chronic kidney disease at the source.
🔬 archbiopartners.com/our-science/ckd-platform
#CKD #KidneyCare #NephSky
Arch is advancing IL-32–targeting drug candidates to address chronic kidney disease at the source.
🔬 archbiopartners.com/our-science/ckd-platform
#CKD #KidneyCare #NephSky
Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023
CKD is a major global health issue, with rising prevalence and increasing importance
as a cause of death and as a risk factor for cardiovascular death. A better understating
of aetiology, appropriate ...
www.thelancet.com
November 19, 2025 at 3:22 AM
📚 @thelancet.com study - www.thelancet.com/journals/lan... - confirms CKD has entered the top 10 causes of death worldwide.
Arch is advancing IL-32–targeting drug candidates to address chronic kidney disease at the source.
🔬 archbiopartners.com/our-science/ckd-platform
#CKD #KidneyCare #NephSky
Arch is advancing IL-32–targeting drug candidates to address chronic kidney disease at the source.
🔬 archbiopartners.com/our-science/ckd-platform
#CKD #KidneyCare #NephSky
🧪 A Life Sciences review (www.sciencedirect.com/science/arti...) confirms that inflammation, vascular injury, and mitochondrial damage drive S-AKI.
These same mechanisms are also active in cardiac surgery-associated AKI (CS-AKI).
🔬 archbiopartners.com/our‑science/lsaltpeptide#AKIK#CSAKIK#NephSkyky
These same mechanisms are also active in cardiac surgery-associated AKI (CS-AKI).
🔬 archbiopartners.com/our‑science/lsaltpeptide#AKIK#CSAKIK#NephSkyky
Models of sepsis-induced acute kidney injury
Sepsis-induced acute kidney injury (S-AKI) is one of the most serious life-threatening complications of sepsis. The pathogenesis of S-AKI is complex a…
www.sciencedirect.com
November 13, 2025 at 7:58 PM
🧪 A Life Sciences review (www.sciencedirect.com/science/arti...) confirms that inflammation, vascular injury, and mitochondrial damage drive S-AKI.
These same mechanisms are also active in cardiac surgery-associated AKI (CS-AKI).
🔬 archbiopartners.com/our‑science/lsaltpeptide#AKIK#CSAKIK#NephSkyky
These same mechanisms are also active in cardiac surgery-associated AKI (CS-AKI).
🔬 archbiopartners.com/our‑science/lsaltpeptide#AKIK#CSAKIK#NephSkyky
📈 A 2025 study in NDT (doi.org/10.1093/ndt/gfaf084) found high kidney failure & mortality rates in IgA nephropathy.
Arch’s CKD platform targets IL-32, a cytokine linked to kidney inflammation, complementing its AKI platform.
🔬 archbiopartners.com/our-science/ckd-platform/
#CKD #KidneyCare #NephSky
Arch’s CKD platform targets IL-32, a cytokine linked to kidney inflammation, complementing its AKI platform.
🔬 archbiopartners.com/our-science/ckd-platform/
#CKD #KidneyCare #NephSky
CKD progression, kidney failure, and mortality among US patients with IgA nephropathy
ABSTRACTBackground and Hypothesis. We assessed disease progression among patients with immunoglobulin A nephropathy (IgAN) and characterized factors associ
doi.org
November 12, 2025 at 11:26 PM
📈 A 2025 study in NDT (doi.org/10.1093/ndt/gfaf084) found high kidney failure & mortality rates in IgA nephropathy.
Arch’s CKD platform targets IL-32, a cytokine linked to kidney inflammation, complementing its AKI platform.
🔬 archbiopartners.com/our-science/ckd-platform/
#CKD #KidneyCare #NephSky
Arch’s CKD platform targets IL-32, a cytokine linked to kidney inflammation, complementing its AKI platform.
🔬 archbiopartners.com/our-science/ckd-platform/
#CKD #KidneyCare #NephSky
📚 An AKI case in @cureusmedical.bsky.social (doi.org/10.7759/cureus.88144) shows how difficult diagnosis can be without clear criteria.
Arch’s ongoing Phase II trial for CS-AKI uses KDIGO to guide consistent diagnosis.
🔬 archbiopartners.com/our-science/lsaltpeptide
#AKI #CSAKI #KDIGO #NephSky
Arch’s ongoing Phase II trial for CS-AKI uses KDIGO to guide consistent diagnosis.
🔬 archbiopartners.com/our-science/lsaltpeptide
#AKI #CSAKI #KDIGO #NephSky
Acute Kidney Injury: A Blocked Diagnosis
Acute kidney injury (AKI) is a common medical condition that we encounter in our daily clinical practice. However, in certain cases, ascertaining the underlying cause of the AKI could be challenging a...
doi.org
November 12, 2025 at 4:32 AM
📚 An AKI case in @cureusmedical.bsky.social (doi.org/10.7759/cureus.88144) shows how difficult diagnosis can be without clear criteria.
Arch’s ongoing Phase II trial for CS-AKI uses KDIGO to guide consistent diagnosis.
🔬 archbiopartners.com/our-science/lsaltpeptide
#AKI #CSAKI #KDIGO #NephSky
Arch’s ongoing Phase II trial for CS-AKI uses KDIGO to guide consistent diagnosis.
🔬 archbiopartners.com/our-science/lsaltpeptide
#AKI #CSAKI #KDIGO #NephSky
🧬 Frontiers in Nephrology (doi.org/10.3389/fneph.2024.1436896) examines chemotherapy-related AKI.
Arch is supporting an ongoing Phase II trial of cilastatin to prevent drug-induced AKI.
🔬 archbiopartners.com/our-science/cilastatin
#AKI #Cilastatin #NephSky #KidneyCare @frontiersin.bsky.social
Arch is supporting an ongoing Phase II trial of cilastatin to prevent drug-induced AKI.
🔬 archbiopartners.com/our-science/cilastatin
#AKI #Cilastatin #NephSky #KidneyCare @frontiersin.bsky.social
Frontiers | Chemotherapy-induced acute kidney injury: epidemiology, pathophysiology, and therapeutic approaches
Despite significant advancements in oncology, conventional chemotherapy remains the primary treatment for diverse malignancies. Acute kidney injury (AKI) sta...
doi.org
November 7, 2025 at 2:52 PM
🧬 Frontiers in Nephrology (doi.org/10.3389/fneph.2024.1436896) examines chemotherapy-related AKI.
Arch is supporting an ongoing Phase II trial of cilastatin to prevent drug-induced AKI.
🔬 archbiopartners.com/our-science/cilastatin
#AKI #Cilastatin #NephSky #KidneyCare @frontiersin.bsky.social
Arch is supporting an ongoing Phase II trial of cilastatin to prevent drug-induced AKI.
🔬 archbiopartners.com/our-science/cilastatin
#AKI #Cilastatin #NephSky #KidneyCare @frontiersin.bsky.social
🚨 Arch Biopartners has announced that the @fraserhealth.ca Research Ethics Board has approved Royal Columbian Hospital to join its Phase II trial of LSALT peptide to prevent CS-AKI.
📖 Latest News at www.archbiopartners.com/investor-hub/
#AKI #CSAKI #KidneyCare #NephSky
📖 Latest News at www.archbiopartners.com/investor-hub/
#AKI #CSAKI #KidneyCare #NephSky
November 5, 2025 at 1:52 PM
🚨 Arch Biopartners has announced that the @fraserhealth.ca Research Ethics Board has approved Royal Columbian Hospital to join its Phase II trial of LSALT peptide to prevent CS-AKI.
📖 Latest News at www.archbiopartners.com/investor-hub/
#AKI #CSAKI #KidneyCare #NephSky
📖 Latest News at www.archbiopartners.com/investor-hub/
#AKI #CSAKI #KidneyCare #NephSky
🧬 @springernature.com - nature.com/articles/s41598-025-18475-z finds DPEP1 blocks NK-cell killing in colon cancer.
LSALT peptide is a DPEP1 inhibitor in a Phase II trial targeting CS-AKI. Approval would validate DPEP1 and open oncology exploration.
archbiopartners.com/our-science
#NephSky #DPEP1
LSALT peptide is a DPEP1 inhibitor in a Phase II trial targeting CS-AKI. Approval would validate DPEP1 and open oncology exploration.
archbiopartners.com/our-science
#NephSky #DPEP1
Attenuation of natural killer cell cytotoxicity by interaction between NKp30 of NK cells and dipeptidase 1 of colon cancer cells - Scientific Reports
Scientific Reports - Attenuation of natural killer cell cytotoxicity by interaction between NKp30 of NK cells and dipeptidase 1 of colon cancer cells
nature.com
October 30, 2025 at 4:42 PM
🧬 @springernature.com - nature.com/articles/s41598-025-18475-z finds DPEP1 blocks NK-cell killing in colon cancer.
LSALT peptide is a DPEP1 inhibitor in a Phase II trial targeting CS-AKI. Approval would validate DPEP1 and open oncology exploration.
archbiopartners.com/our-science
#NephSky #DPEP1
LSALT peptide is a DPEP1 inhibitor in a Phase II trial targeting CS-AKI. Approval would validate DPEP1 and open oncology exploration.
archbiopartners.com/our-science
#NephSky #DPEP1
🚨 Novo Nordisk to acquire Akero Therapeutics in a $5.2B deal, expanding its MASH & metabolic portfolio with a Phase 3 FGF21 analogue @barrons.com: bit.ly/akero-novo-nordisk
Arch develops on-target drugs for AKI & CKD, a condition tied to metabolic dysfunction.
🔬 archbiopartners.com/about-us
#Biotech
Arch develops on-target drugs for AKI & CKD, a condition tied to metabolic dysfunction.
🔬 archbiopartners.com/about-us
#Biotech
Novo Nordisk Is Buying Biotech Akero Therapeutics. The Stock Soars.
Novo Nordisk stock fell after it said it would buy Akero Therapeutics for $54 a share in cash, and an additional $6 if it gets U.S. approval of Efruxifermin, it’s treatment for fatty liver disease.
bit.ly
October 24, 2025 at 4:10 PM
🚨 Novo Nordisk to acquire Akero Therapeutics in a $5.2B deal, expanding its MASH & metabolic portfolio with a Phase 3 FGF21 analogue @barrons.com: bit.ly/akero-novo-nordisk
Arch develops on-target drugs for AKI & CKD, a condition tied to metabolic dysfunction.
🔬 archbiopartners.com/about-us
#Biotech
Arch develops on-target drugs for AKI & CKD, a condition tied to metabolic dysfunction.
🔬 archbiopartners.com/about-us
#Biotech
🚨 Omeros jumps 154% after Novo Nordisk signs a $2.1B deal for Zaltenibart, now in testing for PNH and related kidney disorders.
@ibdinvestors.bsky.social:
bit.ly/omeros-novo-...
Arch Biopartners is developing on-target drugs for AKI and CKD.
🔬 archbiopartners.com/about-us
#Biotech #CKD #NephSky
@ibdinvestors.bsky.social:
bit.ly/omeros-novo-...
Arch Biopartners is developing on-target drugs for AKI and CKD.
🔬 archbiopartners.com/about-us
#Biotech #CKD #NephSky
Small Biotech Catapults 154% On A $2.1 Billion Novo Deal
Novo Nordisk is licensing exclusive global rights to the company's experimental treatment for rare blood and kidney diseases.
bit.ly
October 24, 2025 at 1:34 AM
🚨 Omeros jumps 154% after Novo Nordisk signs a $2.1B deal for Zaltenibart, now in testing for PNH and related kidney disorders.
@ibdinvestors.bsky.social:
bit.ly/omeros-novo-...
Arch Biopartners is developing on-target drugs for AKI and CKD.
🔬 archbiopartners.com/about-us
#Biotech #CKD #NephSky
@ibdinvestors.bsky.social:
bit.ly/omeros-novo-...
Arch Biopartners is developing on-target drugs for AKI and CKD.
🔬 archbiopartners.com/about-us
#Biotech #CKD #NephSky
A 2023 review (www.seminarsinnephrology.org/article/S027... shows how cisplatin causes AKI through inflammation, oxidative stress, and cell injury.
Learn more about the Phase II trial evaluating cilastatin to protect kidneys.
🔬 archbiopartners.com/our-science/cilastatin
#AKI #Cilastatin #NephSky
Learn more about the Phase II trial evaluating cilastatin to protect kidneys.
🔬 archbiopartners.com/our-science/cilastatin
#AKI #Cilastatin #NephSky
Cisplatin Nephrotoxicity: Novel Insights Into Mechanisms and Preventative Strategies
Cisplatin is a highly effective chemotherapeutic agent that has been used for more
than 50 years for a variety of cancers; however, its use is limited by toxicity, including
nephrotoxicity. In this in...
www.seminarsinnephrology.org
October 22, 2025 at 6:09 PM
A 2023 review (www.seminarsinnephrology.org/article/S027... shows how cisplatin causes AKI through inflammation, oxidative stress, and cell injury.
Learn more about the Phase II trial evaluating cilastatin to protect kidneys.
🔬 archbiopartners.com/our-science/cilastatin
#AKI #Cilastatin #NephSky
Learn more about the Phase II trial evaluating cilastatin to protect kidneys.
🔬 archbiopartners.com/our-science/cilastatin
#AKI #Cilastatin #NephSky
📉 Kidney Medicine @kidneymed.bsky.social (Dec 2024): Cilastatin was linked to a 74% lower AKI risk in clinical trials, 46% in observational studies. Overall: 48%.
Arch is supporting the PONTiAK Phase II trial, now recruiting.
🔬 archbiopartners.com/our-science/cilastatin
#Cilastatin #AKI #NephSky
Arch is supporting the PONTiAK Phase II trial, now recruiting.
🔬 archbiopartners.com/our-science/cilastatin
#Cilastatin #AKI #NephSky
Cilastatin – Arch Biopartners
archbiopartners.com
October 21, 2025 at 2:28 PM
📉 Kidney Medicine @kidneymed.bsky.social (Dec 2024): Cilastatin was linked to a 74% lower AKI risk in clinical trials, 46% in observational studies. Overall: 48%.
Arch is supporting the PONTiAK Phase II trial, now recruiting.
🔬 archbiopartners.com/our-science/cilastatin
#Cilastatin #AKI #NephSky
Arch is supporting the PONTiAK Phase II trial, now recruiting.
🔬 archbiopartners.com/our-science/cilastatin
#Cilastatin #AKI #NephSky
📚 @frontiersin.bsky.social 2025 (doi.org/10.3389/fendo.2025.1513008): CKD mortality due to diabetes has nearly tripled since 1990 and is projected to continue rising. Highlights need for on-target CKD treatments.
🔬 archbiopartners.com/our-science/ckd-platform
#CKD #KidneyCare #Nephsky
🔬 archbiopartners.com/our-science/ckd-platform
#CKD #KidneyCare #Nephsky
Frontiers | Global burden of chronic kidney disease due to diabetes mellitus, 1990-2021, and projections to 2050
IntroductionChronic kidney disease (CKD) is a serious complication of diabetes, and the global burden of the disease is gradually increasing.MethodsThis stud...
doi.org
October 20, 2025 at 2:48 PM
📚 @frontiersin.bsky.social 2025 (doi.org/10.3389/fendo.2025.1513008): CKD mortality due to diabetes has nearly tripled since 1990 and is projected to continue rising. Highlights need for on-target CKD treatments.
🔬 archbiopartners.com/our-science/ckd-platform
#CKD #KidneyCare #Nephsky
🔬 archbiopartners.com/our-science/ckd-platform
#CKD #KidneyCare #Nephsky
🌍 @sciam.bsky.social (bit.ly/sci-american...) highlights the global CKD burden and the need for better detection. Heat stress is one factor under study. Arch Biopartners has launched a CKD platform, complementing two Phase II AKI trials.
🔬 archbiopartners.com/our-science
#CKD #AKI #NephSky
🔬 archbiopartners.com/our-science
#CKD #AKI #NephSky
What’s behind the Mysterious Epidemic of Kidney Disease Killing Thousands of Young Men?
As cases of chronic kidney disease emerge in outdoor laborers around the world, scientists are finding that repeated damage from prolonged extreme heat seems to be a leading factor to kidney failure
bit.ly
October 3, 2025 at 9:18 PM
🌍 @sciam.bsky.social (bit.ly/sci-american...) highlights the global CKD burden and the need for better detection. Heat stress is one factor under study. Arch Biopartners has launched a CKD platform, complementing two Phase II AKI trials.
🔬 archbiopartners.com/our-science
#CKD #AKI #NephSky
🔬 archbiopartners.com/our-science
#CKD #AKI #NephSky
📚 Lancet Reg Health – Americas (www.thelancet.com/journals/lan... CKD affects 27% of people with type 1 diabetes in a U.S. cohort; >10% face severe disease.
Highlights urgent need for precise CKD therapies.
🔬 archbiopartners.com/our-science/ckd-platform
#ArchBiopartners #CKD #NephSky
Highlights urgent need for precise CKD therapies.
🔬 archbiopartners.com/our-science/ckd-platform
#ArchBiopartners #CKD #NephSky
www.thelancet.com
October 2, 2025 at 5:08 PM
📚 Lancet Reg Health – Americas (www.thelancet.com/journals/lan... CKD affects 27% of people with type 1 diabetes in a U.S. cohort; >10% face severe disease.
Highlights urgent need for precise CKD therapies.
🔬 archbiopartners.com/our-science/ckd-platform
#ArchBiopartners #CKD #NephSky
Highlights urgent need for precise CKD therapies.
🔬 archbiopartners.com/our-science/ckd-platform
#ArchBiopartners #CKD #NephSky
📚 CDC, 2023 (cdc.gov/kidney-disease/php/data-research/): Over 35 million U.S. adults (more than 1 in 7) have CKD. The data highlights the epidemic scale of the disease and need for on-target CKD treatments.
🔬New CKD platform: archbiopartners.com/our-science/ckd-platform/
#CKD #KidneyCare #NephSky
🔬New CKD platform: archbiopartners.com/our-science/ckd-platform/
#CKD #KidneyCare #NephSky
Chronic Kidney Disease in the United States, 2023
While CKD is common among US adults, people who have CKD can take steps to protect their kidneys.
cdc.gov
September 26, 2025 at 2:04 PM
📚 CDC, 2023 (cdc.gov/kidney-disease/php/data-research/): Over 35 million U.S. adults (more than 1 in 7) have CKD. The data highlights the epidemic scale of the disease and need for on-target CKD treatments.
🔬New CKD platform: archbiopartners.com/our-science/ckd-platform/
#CKD #KidneyCare #NephSky
🔬New CKD platform: archbiopartners.com/our-science/ckd-platform/
#CKD #KidneyCare #NephSky
🚨 Fierce Biotech: “Sparrow flies with $95M for midstage diabetes asset” (fiercebiotech.com/biotech/sparrow-flits-forward-95m-series-b-midstage-diabetes-asset).
Arch Biopartners is a therapeutic biotech with 2 Phase II AKI programs and preclinical IP in CKD.
🔬 archbiopartners.com/our-science/
Arch Biopartners is a therapeutic biotech with 2 Phase II AKI programs and preclinical IP in CKD.
🔬 archbiopartners.com/our-science/
Sparrow flies forward with $95M series B for midstage diabetes asset
Sparrow Pharmaceuticals is looking to send its potential diabetes treatment soaring through clinical trials with the help of a $95 million series B, the company
fiercebiotech.com
September 25, 2025 at 7:09 PM
🚨 Fierce Biotech: “Sparrow flies with $95M for midstage diabetes asset” (fiercebiotech.com/biotech/sparrow-flits-forward-95m-series-b-midstage-diabetes-asset).
Arch Biopartners is a therapeutic biotech with 2 Phase II AKI programs and preclinical IP in CKD.
🔬 archbiopartners.com/our-science/
Arch Biopartners is a therapeutic biotech with 2 Phase II AKI programs and preclinical IP in CKD.
🔬 archbiopartners.com/our-science/
📚 @frontiersin.bsky.social Cardiovasc. Med. (doi.org/10.3389/fcvm.2023.1108538) - 1 in 5 adults with CS-AKI develop CKD within 90 days.
Arch is a therapeutic biotech company supporting two Phase II AKI trials and a CKD platform.
🔬 archbiopartners.com/our-science
#CKD #CSAKI #LSALTpeptide #NephSky
Arch is a therapeutic biotech company supporting two Phase II AKI trials and a CKD platform.
🔬 archbiopartners.com/our-science
#CKD #CSAKI #LSALTpeptide #NephSky
Frontiers | Clinical characteristics and risk factors of cardiac surgery associated-acute kidney injury progressed to chronic kidney disease in adults: A retrospective, observational cohort study
IntroductionTo retrospectively investigate the clinical characteristics and risk factors of cardiac surgery associated-acute kidney injury (CS-AKI) progresse...
doi.org
September 25, 2025 at 3:21 PM
📚 @frontiersin.bsky.social Cardiovasc. Med. (doi.org/10.3389/fcvm.2023.1108538) - 1 in 5 adults with CS-AKI develop CKD within 90 days.
Arch is a therapeutic biotech company supporting two Phase II AKI trials and a CKD platform.
🔬 archbiopartners.com/our-science
#CKD #CSAKI #LSALTpeptide #NephSky
Arch is a therapeutic biotech company supporting two Phase II AKI trials and a CKD platform.
🔬 archbiopartners.com/our-science
#CKD #CSAKI #LSALTpeptide #NephSky